Studies from Institute for Clinical Sciences Describe New Findings in Neoplasms (Specific Uptake In the Bone Marrow Causes High Absorbed Red Marrow Doses During [<superscript>177</superscript>lu]Lu-dotatate Treatment).
In: Hematology Week, 2024-01-15, S. 241-241
serialPeriodical
Zugriff:
A recent study conducted in Gothenburg, Sweden, has found that bone marrow suppression is a common side effect of [Lu-177]LuDOTATATE treatment for neuroendocrine neoplasms. The study aimed to identify and quantify specific red marrow uptake using SPECT/CT images collected after the first treatment cycle. The results showed increased uptake of [Lu-177]Lu-DOTATATE in the vertebrae and hip bones of all 17 patients compared to activity concentrations in the aorta. The study concluded that blood-based dosimetry methods underestimate the absorbed dose to red marrow and fail to account for the prolonged elimination of specific uptake. [Extracted from the article]
Copyright of Hematology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Studies from Institute for Clinical Sciences Describe New Findings in Neoplasms (Specific Uptake In the Bone Marrow Causes High Absorbed Red Marrow Doses During [<superscript>177</superscript>lu]Lu-dotatate Treatment).
|
---|---|
Zeitschrift: | Hematology Week, 2024-01-15, S. 241-241 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-673X (print) |
Schlagwort: |
|
Sonstiges: |
|